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Summary
Kienböck’s disease is a rare condition characterised by 
avascular necrosis of the lunate bone. Its natural history 
and aetiopathogenesis have not yet been clarified, 
nor are its triggering factors identified. We present a 
case of a 17-year-old male gymnast, without relevant 
medical/family history, with stage IIIa Kienböck’s disease 
diagnosed in 2016. Initially, submitted to conservative 
treatment that proved to be insufficient. Consequently, 
surgical treatment was proposed, but refused. the 
patient instead underwent experimental treatment with 
hyperbaric oxygen (120 sessions, 100% oxygen at 2.5 
atm, for 70 min periods, once daily, five times per week). 
In april 2018, a favourable clinical and radiological 
evolution was observed, with an improvement in the 
patterns of pain, motion and strength and an almost 
complete involution of the process of aseptic necrosis of 
the semilunar. to the best of our knowledge, this is the 
first report of Kienböck’s disease treated with hyperbaric 
oxygen.
BaCkground 
Kienböck’s disease is characterised by avascular 
necrosis of the lunate bone. The complete patho-
physiology of this disease is yet to be understood, 
but it seems to relate to an apparent combination of 
vascular, anatomic and traumatic insults, resulting 
in progressive bone infarction and collapse with 
biomechanical compromise. Generally, it afflicts 
mostly adults between 20 and 40 years of age, typi-
cally male manual workers. Its natural history is not 
well known, and the clinical features do not neces-
sarily correlate with the radiological findings that 
are most times the cornerstone of the diagnosis.
The main objective of the treatment is to relieve 
pain. However, despite the different therapeutic 
approaches mainly based on the radiological stage, 
there is no gold standard for Kienböck’s disease. 
For stages II and IIIA of the disease, the treatment 
is centred on joint levelling and/or revascularisation 
procedures. We present a case of a young patient 
with Kienböck’s disease stage IIIA who underwent 
treatment with hyperbaric oxygen therapy (HBOT). 
As a complementary treatment, this strategy has 
been reported to improve the outcomes in patients 
suffering from femoral head necrosis. To the best of 
our knowledge, this is the first report of Kienböck’s 
disease treated with this non-surgical approach.
CaSe preSenTaTion
A 17-year-old male gymnast, without relevant 
medical and family history, reported in February 
2016 pain in his left wrist with 2 weeks of evolution 
and no associated traumatic event. The pain was 
constant (5 points at Visual Analogue Scale, VAS), 
located at the level of the scaphoid–lunate space, 
with no irradiation and worsened by the dorsi-
flexion of the wrist.
The patient performed a wrist radiograph that 
revealed no acute osteoarticular lesions or degen-
erative changes. Analgesics and eviction of manual 
physical efforts were prescribed. After 3 months, 
there was a recurrence and worsening of pain with 
crepitus and repercussions in daily life (7 points at 
VAS) and sports activities (10 points at VAS). The 
wrist’s mobility was minimal because it triggered 
maximum pain. Severe night and light touch pain 
were present. A new radiographic study revealed a 
subchondral sclerosis of the lunate (figure 1). MRI 
confirmed the diagnosis of Kienböck’s disease, stage 
IIIA of Lichtman classification (figure 2A–C). An 
elective hospitalisation was proposed for surgical 
treatment with radius shortening osteotomy. 
However, the patient and his family were sceptical 
of this invasive approach. Therefore, this procedure 
was postponed in favour of a conservative treatment 
with a plaster cast forearm immobilisation for 50 
days and a potential treatment with HBOT. After 
this, the use of a forearm orthosis for pain relief 
was recommended. Due to bureaucratic and logis-
tical issues, there was a 5-month gap until starting 
HBOT. In January 2017, the patient started HBOT 
in a multiplace hyperbaric chamber, exposed to 
100% oxygen at 2.5 atm, for 70 min periods, once 
daily, five times per week. In a first stage, 30 sessions 
were prescribed, after which the patient attended 
an evaluation. During this consultation, the patient 
reported significant improvement in mobility, pain 
intensity and oedema resolution, with a progressive 
increase in grip strength and the need for further 
treatment was decided. After an evaluation MRI 
(session 77th) showing an important radiological 
response (figure 2D), the decision was to extend the 
treatment to 120 sessions.
ouTCome and follow-up
In the last follow-up consultation (April 2018), the 
patient presented mild pain, only for activities of 
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axial load sport’s related (VAS 4), carpus’s crepitation with wrist 
ulnar deviation and a slight pain and decrease of the extension 
of the fist in the last degrees of extension (joint painless range of 
motion for 90°—figure 3). Functional evaluation was performed, 
using the Patient-Rated Wrist Evaluation score (7 points), the 
disabilities of the arm, shoulder and hand score—QuickDASH 
(0 points) and QuickDASH sports performing (75 points). Grip 
strength and mobility were evaluated by comparison with the 
unaffected side. These parameters did not reveal significant alter-
ations compared with the contralateral side. Notwithstanding, 
the absence of pain and good mobility for daily activities, the 
patient maintains a limitation to the previous sporting practice. 
The MRI revealed (figure 2E–F) almost complete involution of 
the process of aseptic necrosis of the semilunar.
We believe that the follow-up period should include a semian-
nual consultation during the first 2 years, followed by an annual 
appointment.
diSCuSSion
Kienböck’s disease is a rare condition. Its natural history and 
aetiopathogenesis have not yet been clarified, nor its triggering 
factors identified.1 2 It is believed, as in the works published 
by Kienböck, that traumatic event associated with ligament 
and vascular injury may be implicated in the mechanism of 
the disease, and there are presently three coexisting theories: 
mechanical, vascular and traumatic theory.3
This condition has a higher predominance for males, espe-
cially in individuals with a strong impact on manual labour tasks. 
However, the incidence and prevalence of this disease in athletes 
is unknown.3
The vascularisation of the lunate occurs by dorsal and palmar 
branches of the radial and ulnar arteries. It is estimated that only 
in 20% of the cases the palm branches are found conferring 
an increased risk of osteonecrosis.4 The vascularisation of the 
proximal pole is more exiguous which predisposes to avascular 
necrosis events with increased probability.3
The initial clinical manifestation may be subtle but may mimic 
a wrist sprain or any inflammatory condition affecting the limb.3 
Dorsal and palmar oedema and crepitation to palpation stand 
out. Joint mobility may be affected by the associated pain, aggra-
vated by maximal flexion and extension, thus assuming pain as 
the main factor of dysfunction,1 there may also be a decrease 
in grip strength.2 This episodic pain may be associated with the 
period of fragmentation caused by fracture of the subchondral 
figure 1 Frontal radiograph of the left wrist before HBOT. There are 
diffuse heterogeneity and sclerosis of the lunate bone. Negative ulnar 
variance is noted. HBOT, hyperbaric oxygen therapy.
figure 2 Left wrist MRI images before (A–C), during (D) and 
after (E and F) HBOT. (A) T1-weighted coronal image shows diffuse 
hypointensity, heterogeneity and altered trabeculation of the lunate 
bone (arrow). (B) Fat-saturated proton density-weighted sagittal image 
depicts areas of hyperintensity (*) traducing bone marrow oedema 
and intraosseous cystic lesions (dashed arrow). (C) T2*-weighted 
gradient-echo coronal image depicting partial bone collapse (*) as well 
as fragmentation (arrow) on the radial side of the lunate bone. (D–F) 
Images on the same MRI sequences as A, B and C, respectively, after 77 
(D) and 120 (E and F) sessions of HBOT, show a significant improvement 
of disease with remission of previous changes. There is a practically 
complete recovery of the signal and homogeneity of lunate bone 
(arrows). HBOT, hyperbaric oxygen therapy. 
figure 3 Patient’s range of movement.
3Figueira PJ, et al. BMJ Case Rep 2018. doi:10.1136/bcr-2018-226090
novel treatment (new drug/intervention; established drug/procedure in new situation)
bone, absence of restriction of joint mobility and concomitant 
synovitis.1
The clinical suspicion for the diagnosis, combined with an MRI 
allows for detecting the disease at an earlier stage. Thus, the T1 
and T2 changes in the signal can detect changes in the vasculari-
sation2 with bone necrosis,3 allowing for the establishment of an 
earlier therapeutic protocol.1 The implementation of this protocol 
allows monitoring the evolution of the treatment conferred by 
the hypersignal in T2 that manifests bone revascularisation.2
The presumptive diagnosis presupposes the exclusion and 
control of several clinical conditions that may contribute to 
the aetiopathogenesis of this condition, such as coagulopathies, 
haemoglobinopathies, lupus, arterial disease, conditions that 
favour venous stasis (obesity), alcohol consumption and anabolic 
steroids.1–3 5
Regardless of the treatment selected, its primary goals should 
be to relieve pain, prevent bone collapse and prevent or delay 
osteoarthritis. There are currently several treatment modal-
ities, varying from the conservative methodology with immo-
bilisation and anti-inflammatory drugs and change in lifestyle,3 
to numerous surgical approaches, none of which is presently 
considered the gold standard in the treatment of this pathology.1 
Procedures such as lunate revascularisation, osteotomies or for 
the treatment of sequelae caused by the collapse of the lunate 
(graft, vascularised graft, prosthesis, proximal carpectomy, 
arthroplasty or arthrodesis) are well known.4 6
From the review of the initial imaging study, we can conclude 
that in the present case, we were faced with a stage IIIA lesion 
of the Lichtman classification. The most consensual therapeutic 
options for treatment of stage IIIA are radio-osteotomies, vascu-
larised bone grafts, temporary scaphocapitate osteotaxia or 
scaphotrapeziotrapezoid, capitate shortening with or without 
capitohamate arthrodesis.2
Despite the surgical technique applied, the outcome regarding 
bone regeneration has not yet been established.7 In this sense, 
other approaches were developed such as transfusion of bone 
marrow after microperfurations stabilised with osteotaxy and 
low-intensity pulsed ultrasound with a demonstration of non-in-
feriority results, postulating possible effect of the properties of 
mesenchymal stem cells and cytokines and growth factors with 
neovascularisation properties.7
Therefore, considering promising work already published 
on the effects of HBOT: (1) the biological potential of the 
mesenchymal cells, (2) the wound healing physiology, (3) the 
angiogenic potential effect associated with the treatment of 
osteonecrosis of the femoral head; in addition to the patient’s 
family reluctance towards the surgical option, we opted for the 
conservative approach using HBOT.
The precise role of HBOT is not yet established. It is now 
known that HBOT allows for higher concentration and diffusion 
in the blood plasma and consequently the level of oxygenation 
in the tissues. In parallel, microvascular perfusion is stimulated 
by the synergistic effect of increased synthesis of nitric oxide.8 
HBOT seems to contribute to the reduction of bone and periph-
eral oedema, facilitating venous drainage and promoting angio-
genesis by contributing to the cellular stimulus inducing the 
formation of fibroblasts and formation of collagen9 through 
mechanisms that stimulate the production of antioxidant 
enzymes with the production of cytokines and growth factors.8 
In addition, angiogenesis may be enhanced by the recruitment 
of bone marrow stem cells under the effect of HBOT, with 
emphasis on the endothelial progenitor cells.10–12
Concomitantly, hyperoxia acts on bone metabolism by stimu-
lating osteoclastic activity on the necrotic bone.2 9 Animal studies 
have shown that areas with capillary proliferation and fibro-
blastic activity stimulate osteoblastic and osteoclastic activity 
promoting the replacement of necrotic bone with new bone.6 
The key factor here seems to be the balance between osteoblastic 
and osteoclastic activity. At the cellular and molecular levels, 
the beneficial effects of HBOT may be via regulating serum 
osteoprotegerin, accelerating osteoblast differentiation and 
suppressing osteoclasts genesis activation, shifting the balance 
between bone formation and bone resorption in a direction that 
promotes bone regeneration.13
The HBOT sessions, in this case, were held inside a hermet-
ically sealed hyperbaric chamber classified as type IIb medical 
device (Directive 93/42 ECC of 14 June 1993, concerning 
medical devices). The patient performed our routine protocol 
(100% oxygen at 2.5 atm, for 70 min periods, once daily, five 
times per week) for general medical conditions. This treatment 
included a total of 120 sessions with two intervals coincident 
with the school holidays (2 weeks within the first 30 sessions 
and 8 weeks between 60 and 90 sessions). The first cycle of 30 
sessions had a marked impact on the mobility gain, which we 
associate with the rapid resolution of oedema and pain manage-
ment. During the treatment, clinical and radiological improve-
ments were observed, triggering our decision to have the patient 
undergo more than 100 treatment sessions, surpassing the 
number established for other chronic conditions treated at our 
centre.
Despite this favourable clinical outcome, there are some unan-
swered questions, namely: in light of the current evidence related 
to the natural history of this disease, can we assume that an adoles-
cent could have a stage IIIA spontaneous remission? This fact is 
known to be more frequent at the paediatric age14–16; however, 
while awaiting the start of HBOT there was no improvement in 
symptoms. Could interruption of our protocol have influenced 
the result obtained, even in the absence of cumulative side effects 
of hyperoxia (Lorrain-Smith and Paul Bert’s effects)? Could the 
repetitive microtrauma associated with our patient’s competi-
tion gym explain the occurrence of his illness? Is the patient fit 
in the medium to long term to resume his high-impact sports 
activities? On the objective clinical and functional evaluation of 
the patient’s evolution during the HBOT period, there are some 
biases to disclose: the retrospective assessment of pain and func-
tional scales, the absence of quantitative determination of the 
mobility and grip strength, the failure to perform arthroscopy 
for the initial in loco staging disease for improved characterisa-
tion of joint surfaces and eventual ligament dysfunction.
The indications for HBOT are well defined in the 10th Euro-
pean Consensus Conference on Hyperbaric Medicine held in 
2016. Its use for the treatment of osteonecrosis of the femoral 
head is a type II indication and its application in Kienböck’s 
disease continues to be off-label.8 16 The success obtained with 
learning points
 ► Kienböck’s disease is a rare condition requiring a high index 
of suspicion.
 ► There is currently no gold-standard treatment.
 ► The current surgical treatments do not seem to totally change 
the natural history of the disease.
 ► Hyperbaric oxygen therapy (HBOT) may take place as a new 
successful therapeutic strategy.
 ► Can HBOT change the natural history of the disease in the 
long term?
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this treatment could lead to HBOT implementation for Kien-
böck’s disease, bringing great value added to the existing thera-
peutic arsenal. Therefore, this conservative treatment may be a 
valid option for this clinical context, requiring: (1) more cases 
to be treated with HBOT, (2) a specific HBOT protocol, (3) a 
longer follow-up period (possibly up to 30 years) and (4) a cost–
benefit analysis versus other therapeutic approaches.
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